key: cord-0911668-5d8v3yxn authors: Mohseni Afshar, Zeinab; Babazadeh, Arefeh; Hasanpour, Amirhossein; Barary, Mohammad; Sayad, Babak; Janbakhsh, Alireza; Aryanian, Zeinab; Ebrahimpour, Soheil title: Dermatological manifestations associated with COVID‐19: A comprehensive review of the current knowledge date: 2021-07-16 journal: J Med Virol DOI: 10.1002/jmv.27187 sha: 4cbbc6469574df37fab216252eb3561dc51d070d doc_id: 911668 cord_uid: 5d8v3yxn Coronavirus disease 2019 (COVID‐19) caused by severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) has become a significant health problem globally. The virus has spread widely and become a global pandemic. The pathophysiology for SARS‐CoV‐2 has not been explained clearly. It has been associated with several multiorgan symptoms, among which its dermatological manifestations are of great interest. Primarily, there has been no report of skin features among COVID‐19 patients. Nevertheless, recently there have been several reports regarding COVID‐19 patients who presented with cutaneous manifestations. In the current review, we focus on the various cutaneous manifestations of COVID‐19 infection. The presence of the angiotensin-converting enzyme 2 (ACE2), which is the primary receptor for SARS-CoV-2 entering skin cells, might explain some of the vascular skin lesions of COVID-19 infection due to significant immune antiviral response. 9 The virus can directly induce cutaneous lesions or indirectly due to vascular dysfunctions, such as imposed vasculitis and thrombotic vasculopathy. The former may occur through direct viral inoculation, viral reactivation from a distant site, or immunotherapy. 10 Figure 2 illustrates a summary of the cutaneous manifestations of COVID-19. F I G U R E 2 A summary of cutaneous manifestations of COVID-19 MOHSENI AFSHAR ET AL. | 5757 3 | MORPHOLOGY Dermatological manifestations of COVID-19 are significantly more polymorphic than any viral infection so far. 11 Maculopapular, vesicular, and urticarial lesions are the most common cutaneous eruptions, respectively. 3 Several studies have been conducted to build consensus on categorizing COVID-19 skin presentations as follows. Before the SARS-CoV-2 pandemic, many viral and bacterial pathogens such as cytomegalovirus (CMV), herpes simplex virus (HSV), Epstein-Barr virus (EBV), and mycoplasma were prevalent infectious triggers of urticarial eruptions and angioedema. 12 Itching is almost always present under these circumstances. This dermatological complication usually takes one week to resolve during moderate to severe COVID-19 in approximately 20% of the patients. 13 These lesions are frequently localized on the trunk and extremities, usually with sacral sparing. 14 As with other hypersensitivities and allergic dermatitis, low-dose oral corticosteroids, in addition to antihistamines, can provide appropriate relief. 15 Occurring in about 21.3% of the patients, these eruptions are sometimes pruritic and usually appear on the trunk and extremities. They may appear at the same time or evolve from mild involvement to a more diffuse pattern. These lesions can result from SARS-CoV-2 itself, or drugs used to treat COVID-19 infection, are variably pruritic and can last up to one week. 16 Topical glucocorticoids, and in more severe cases, systemic corticosteroids can provide a suitable remedy. 17 These lesions can differ from diffuse polymorphic eruptions to a localized monomorphic pattern, usually on the chest, upper abdomen, or back. 18 Affecting about 29.4% of the patients, their duration can range from a few days up to 2 weeks, and they mainly occur in the context of moderate to severe COVID-19. 19 These eruptions are also known as "varicella-like" eruptions because of their morphology and common characteristics common to the varicella-zoster virus (VZV). However, as the VZV can also be superimposed on pre-existing COVID-19, 20 performing a Tzanck smear or polymerase chain reaction (PCR) of the vesicle fluid may be beneficial in excluding herpesviruses as the inciting factor. 21 The lesions are usually non-pruritic, do not leave scars and are self-limiting. 22 Some studies have included Grover's disease in the category of papulovesicular eruptions associated with COVID-19. 23 It is believed that some papulovesicular eruptions of COVID-19 may be the "pseudo-herpetic" variant of Grover's disease. 24 3.4 | Chilblain-like acral pattern These lesions are defined as erythematous-violaceous patches or plaques usually located on the feet, sometimes on the hands, and rarely on the auricular area. They may be accompanied by itching, pain, or a burning sensation. "COVID toes," also known as pseudo-chilblain or pernio-like lesions, are vasculopathy rashes located in acral areas affecting up to 63% of the patients. 25 The eruptions usually occur in mild or even asymptomatic cases of COVID-19 and more commonly in children and young adults. 26 Increased interferon release due to the cytokine response, direct viral damage of the endothelium, obliterative microangiopathy, and coagulopathy resulting from ischemia can be the causative mechanisms. These lesions tend to subside spontaneously as well. 27 This skin involvement appears as a cross-linked pattern accompanied by bluish discoloration of the skin and can occur either as a typical livedo reticularis or livedo racemosa. 28 May involves about 6% of the patients, 25 these lesions are first symmetrical and lace-like, resulting from cutaneous vasoconstriction or vascular flow disturbances and disappearing by themselves. 29 On the other hand, the latter usually consisted of more oversized, more irregular, and asymmetrical lesions related to focal blood flow disturbances and may be associated with severe coagulopathies. These eruptions are more common in the elderly and patients with severe COVID-19 infection. Both types are usually self-limited. 29 3.6 | Purpuric "vasculitic" pattern This cutaneous manifestation is usually due to vasculitic changes resulting from direct endothelial lesions or exaggerated inflammatory reactions. They are sometimes accompanied by necrotic lesions and can be diffusely distributed in the intertriginous areas or localized peripherally. 30 The same lesions are in the form of polyarteritis nodosa associated with hepatitis B infection. 31 Kawasaki-like eruptions caused by COVID-19 in children are thought to have a vascular origin, 32 which can be misdiagnosed as dengue virus-induced eruptions in endemic regions. 33 Consequently, viral hemorrhagic fevers should always be included in the differential diagnoses. Mild cases can be treated with topical glucocorticoids, while more severe cases need systemic corticosteroids. 34 Although not classified, ischemic and ecchymotic acral lesions have been reported in almost 10% of the patients, especially in those with severe COVID-19 infection due to hypercoagulation and disseminated intravascular coagulation. COVID-19-related acral lesions have been distributed on the extremities' digital, dorsal, and ventral surfaces and the heels and wrists. 35 3.7 | The erythema multiforme-like lesions These lesions are characterized by annular erythematous macules and vesicles with a darker center and paler halo. In the context of COVID-19, these lesions may be smaller than the classic form and may not demonstrate target-shaped or iris-like features. 36 Several other lesions have been reported for COVID-19, some of which cannot be categorized into one of the mentioned groups. Examples include pityriasis rosea-like rash, 37 Grover's disease-like eruptions, 23, 38 acro-ischemia, 39 malar erythema, and facial edema, 40 palmar erythema, 41 symmetrical drugrelated intertriginous and flexural exanthema (SDRIFE)-like eruptions, 42 hand-foot-mouth-like diseases, 24 "COVID toes" or pernio-like eruptions, 43 Dengue-like rashes, 33 diffuse melanoderma, 44 gangrene, 45 paronychia, 46 sacral and buttocks ulcerations, 47 with "porcelain-like" appearance, 53 IgA vasculitis, 54 leukocytoclastic vasculitis, 55 retiform purpura, eosinophilic panniculitis, 56 and periorbital dyschromia. 57 The impact of COVID-19 on hair can be described under four categories. Telogen effluvium (TE) is a widespread form of hair loss characterized by a diffuse hair loss resulting from a stressor that disturbs the hair cycle's adjustment and causing it to enters the telogen phase earlier. Infection with COVID-19 may be a significant trigger for TE, possibly due to psychosocial or physiological stress. Sudden and excessive hair loss and temporary alopecia may occur during SARS-CoV2 infection, like any other infection, due to COVID-19 related to anagen effluvium (AE) resulting from the severe inflammatory response. 58 Alopecia areata (AA) is a chronic autoimmune disease characterized by sudden hair loss coursing with spontaneous remission and exacerbation. In several COVID-19 patients, acute or chronic psycho-emotional stress may cause AA's onset or progression, presented as alopecia totalis or alopecia universalis. The relationship between SARS-CoV-2 infection and the androgenic pathway has been previously explained, and several cases of androgenetic alopecia have been reported in COVID-19 patients. 59 Polydactylous erythronychia or "COVID red half-moon" nail sign is manifested by distal half-moon-shaped red bands surrounding the distal part of the lunula on fingernails, 60 which is the result of capillary changes to the nail fold bed indicative of microvascular involvement. 61 Locations of the cutaneous lesions vary widely. Some are located on the trunk, while others are focused on the extremities. 62 Some of the lesions may occur during the onset of typical COVID-19 symptoms, while others may occur before or after the onset of other symptoms. In cases where skin eruptions occur before COVID-19 general manifestations, asymptomatic carriers are suspected, while in cases that develop cutaneous lesions during the course of the infection or after recovery, the immunological response is more likely suspected. 3 The presence of skin lesions may not be affected by the severity of COVID-19. 63 However, cyanosis, purpura, haemaphysalis, and gangrene, which result from multiple organ injuries and ischemia, are primarily observed in severe forms of COVID-19 infection. 64 Age is also an essential factor in the type of dermatological involvement in COVID-19. For example, compared to adults, children usually presented with chilblain-like, papulovesicular, or Kawasaki disease-like eruptions, mostly on acral areas. 26 On the other hand, MOHSENI AFSHAR ET AL. | 5759 older adults are more vulnerable to stasis dermatitis than others. Becoming sedentary due to isolation and social distancing measures is the primary risk factor for this condition, which, with the alteration of venous drainage of the lower limbs, results in this complication in geriatrics. 65 The skin manifestations of COVID-19 among children are somewhat different from those of adults. 66 Urticarial, vesicular, purpuric, and livedoid eruptions are the most frequent skin eruptions in pediatrics. 67 Moreover, pityriasis rosea-and chilblains-like lesions 68 are more common in children than adults. 26 Neonatal rashes, including erythematous maculopapular eruptions, have been demonstrated in newborns infected with COVID-19. 69 A Kawasaki-like manifestation has recently been attributed to SARS-CoV-2 infection, called multisystem inflammatory syndrome (MIS). 70 This condition, which is of vasculitic origin, is presented with mucocutaneous involvement, including polymorphic eruptions, palmar and plantar erythema, and other Kawasaki disease features. 71 Most skin lesions associated with COVID-19 can disappear spontaneously, while others may persist longer. This duration has been reported as hours to weeks. 72 As various medications are being tried and used to treat COVID-19 infection, skin reactions to drugs are common in these patients. Adverse skin reactions associated with the medication may be immediate or delayed hypersensitivity reactions. 6 The drug-induced urticaria eruption mediated by IgE, activation of mast cells, immune complexes, or supplements can manifest as the first episode or may present with exacerbation of the pre-existing urticaria. 15 A drug-induced maculopapular eruption that may be associated with eosinophilia results from a perivascular cutaneous lymphohistiocytic infiltrate. 73 Severe cutaneous adverse drug reactions like DRESS (drug reaction with eosinophilia and systemic symptoms) are generally associated with liver abnormalities, eosinophilia, facial swelling, and lymph node involvement. 50 Vasculitis induced by drugs such as livedo racemosa or purpura, which results from complex immune deposits, is a typical presentation following drug consumption. 74 The type of drug eruptions is, to some extent, dependent on the medication used. Antivirals, antibiotics, anticoagulants, biologic drugs, and immunosuppressive and immunomodulatory agents are applied separately or simultaneously, leading to drug-induced skin eruptions. 75 Hydroxychloroquine is the most known drug responsible for drug eruptions caused by COVID-19. 76 This agent may cause multiple skin lesions like hyperpigmentation, 77 hair whitening, 78 and psoriasis exacerbation. 79 Stevens-Johnson syndrome (SJS) 80 and acute generalized exanthematous pustulosis (AGEP) 81 were also reported in a patient with COVID-19 treating with hydroxychloroquine. However, these effects are primarily associated with high doses of the drug. 82 Hair loss and photoallergic eczematous reactions with ribavirin, 83 maculopapular eruptions and AGEP with lopinavir/ritonavir, 84 urticaria, generalized eczema and papules with interferons, 85 AGEP, 86 DRESS, 87 and SJS 88 with tocilizumab, and rare cases of maculopapular rashes associated with remdesivir have also been reported. 89 Furthermore, mechanical pressure due to noninvasive ventilation (NIV) oronasal mask can cause discomfort and perioral pressure ulcers, particularly in patients with delicate, sensitive skin. 86 Moreover, xerostomia induced by NIV can lead to mouth ulcers. 90 Dermatological events related to COVID-19 occur due to viral infection or adverse reactions to medications used to treat it. 91 One way to distinguish these two entities is the presence of enanthema (oral cavity lesions), which favors viral-induced eruptions. 92 The histopathological features of COVID-19-associated skin lesions are various and primarily associated with the lesions' morphologic type. As COVID-19-related skin lesions are nonspecific, histopathology can have an essential role in their characterization during the current pandemic. 95 The following features have been demonstrated in the histopathological examination of COVID-19-related cutaneous lesions: The predominant histopathological findings of erythematous lesions are the superficial perivascular lymphocytic infiltration, focal acantholytic suprabasal clefts, dyskeratotic, and ballooning herpes-like keratinocytes, and swollen vessels with dense lymphocyte infiltration. 96 Varicella-like papulovesicular exanthems, recommended to be named "COVID-19-associated acantholytic rash," are vacuolar degenerations of the basal layer with multinucleate, hyperchromatic keratinocytes and dyskeratotic cells and inflammatory infiltrate, acantholysis, intraepidermal vesicles with suprabasal clefts. Histopathological findings can vary from an erythema multiformelike pattern, such as vacuolar interface dermatitis and necrotic keratinocytes, to lichenoid dermatitis, accompanied by spongiosis dyskeratotic basal keratinocytes, and superficial perivascular lymphocytic infiltrate. 19 Histopathological findings of these lesions include acantholysis and dyskeratosis associated with the presence of a unilocular intraepidermal vesicle in a suprabasal location and ballooned keratinocytes. 97 They are necrotic epidermal keratinocytes accompanied by dermal edema and diffuse dense lymphoid infiltrate of the superficial and deep dermis and hypodermis. They have a general perivascular pattern and signs of endothelial activation, such as endotheliitis, occasionally red cell extravasation, focal thrombosis in papillary dermal capillaries, and vessels of the reticular dermis, 98 and perieccrine sweat gland lymphocytic inflammation. 39 It is a pauci-inflammatory thrombogenic vasculopathy accompanied by extensive deposition of C5b-9 and C4b within the microvasculature. 99 15.7 | Purpuric "vasculitic" pattern They can be defined as leukocytoclastic vasculitis, with neutrophilic infiltrate within the small vessel walls, lymphocytic perivascular infiltrates, and the presence of fibrin and endothelial swelling. 100 It is a diffuse spongiosis in the epidermis and rounded spongiotic vesicles containing aggregates of lymphocytes and Langerhans cells with mild papillary edema and lymphohistiocytic infiltrate in the dermis. Lobular panniculitis with the presence of lymphocytes, histiocytes, and eosinophils is consistent with eosinophilic panniculitis. 118 Another challenge COVID-19 has posed in the dermatology field is the potential delay of skin cancers (BCCs, SCCs, melanoma, non-melanoma cancers, and hemangioma) diagnosis and treatment. 119 This delay may lead to unfavorable outcomes, including wider excision, metastasis, and death. 120 The skin is the first and foremost defense barrier against many infections, insults, contaminations, and traumas. Therefore, disruption of its integrity can lead to many complications. 121 Thus, it can be damaged by protective measures through two mechanisms: 1. Skin injury due to PPE. 2. Skin damage as a result of excessive hand sanitizer use. 122 The great need for hand washing and implementing precautionary prevention measures, such as putting on gloves and goggles, has given rise to a new set of problems in the COVID-19 era. 107 Cutaneous complications due to preventive measures are more prevalent among healthcare workers (HCWs). HCWs wash their hands 20 times a day on average, while hand washing more than 10 times a day is reported to harm the skin adversely. 123 The new term, "COVID hand dermatitis," is proposed for irritant dermatitis during the COVID-19 period. 124 Sanitizers such as alcohol-based hand-rubs disrupt the epidermal barrier due to their lipid solubility, leading to a burning or stinging sensation followed by itching and scratching. 125 Constant goggle-, face shield-, and maskwearing can lead to ulceration, abrasion, and pressure sores on the face which not only is a bothersome cosmetic problem but also can reduce the efficacy of protective mask due to becoming unfit as a result of involuntary manipulations done to decrease the pressure. 126 The most common sites of facial skin damage are the nasal bridge, cheek, and forehead. 127 Moreover, frequent hand washing can lead to tinea or candida infection. Gloves, especially latex ones, are also significant causes of contact dermatitis. Latex-free gloves can be a reasonable solution to this pandemic-related problem. 128 In general, occupational skin complications during the COVID-19 pandemic can be classified into four subgroups. This entity results from direct trauma and pressure on the skin epidermis and dermis beneath the PPEs. The most common lesions are nasal bridge ulcerations. Erythema, papules, maceration, and scaling on the nose, cheeks, forehead, and hands are other findings. Burning, itching, and stinging sensations are the apparent features. This condition is more prominent in men than women and can be controlled with hydrocolloid dressings and emollients at pressure sites. 129 This condition is due to maceration and occlusion of skin pores, elevated skin temperature, humidity, excessive water immersion, or hyperhydration. The most commonly involved areas are the folds and interdigital webs and manifest as erosions, intertrigo, tinea, immersion foot, dyshidrosis, or miliaria. 130 Interestingly, a case of aquagenic syringeal acrokeratoderma or transient aquagenic palmar hyperwrinkling has been reported due to prolonged water immersion. 131 This complication can be managed with topical aluminum, calcium or zinc preparations, antifungals or steroids, or topical antibiotics if superinfected. 129 This event can be either irritant dermatitis or allergic dermatitis; they are mainly located on the face and hands, places which are covered with gloves and masks; however, occupational airborne ACD due to formaldehyde 132 and retro-auricular dermatitis due to face mask ear loops have also been reported. 133 This condition is most commonly associated with detergent use or latex gloves and can present with dry, pruritic, or chapped skin with apparent erythema, papules, scaling, and fissures. 7 This complication can be easily managed with topical steroids or calcineurin inhibitors, H 1antihistamines, and emollients. 129 Chronic skin disorders that can be aggravated in this setting include acne, rosacea, perioral dermatitis, seborrheic dermatitis, and atopic dermatitis. Nevertheless, these conditions can be managed individually depending on that specific dermatosis. Prolonged hours of protective gloves use can induce pruritus and folliculitis. Moreover, increased humidity due to prolonged mask-wearing can result in pilosebaceous duct occlusion and acne exacerbation. 134 All the mentioned dermatologic complications can be prevented by several measures, including reducing or avoiding contact with the responsible PPE (e.g., gowns, goggles, gloves, helmet, boots, or masks), taking 15-min breaks every 2 h at duty, 135 using foam dressing, barrier creams or skin powder beneath the PPE, using ear savers, 136 checking the appropriate size of the PPE, using emollients whenever the PPE is put off, using pH-neutral, soap-free cleansing agents for personal hygiene, 129 avoiding excessive washing of the skin and frequent disinfectants use, 137 avoiding tight gowns and ingestion of sufficient amounts of liquids 138 and use of low pH disinfectants and moisturizers. 65 Exanthematous COVID-19 related eruptions can be relieved by medication such as topical corticosteroids. 139 As skin injuries are more common in HCWs, they should apply measures to relieve newonset skin involvement in primary stages. They can use moisturizers and low potency topical steroids for xerosis and mild dermatitis. However, antihistamines and more potent topical steroids are indicated for severe, more pruritic lesions. 140 Vascular skin lesions in the settings of hypercoagulable conditions, such as acro-ischemic, purpuric, and livedoid lesions, or leukocytoclastic vasculitis, usually subside when COVID-19 resolves; however, anticoagulant therapy is the primary key for their improvement. If secondary bacterial or fungal infection is superimposed on COVID-19 related cutaneous complications, an antimicrobial or antifungal agent can be administered. 137 In cases of pre-existing dermatoses exacerbation, prompt dermatologist referral is recommended. 122 For drug-induced cutaneous rashes, temporary or persistent discontinuation of the responsible medication may be needed. 4 Clinical and laboratory findings from patients with COVID-19 pneumonia in Babol North of Iran: a retrospective cohort study Neurologic manifestations in patients with COVID-19: a case report SARS-CoV-2, COVID-19, skin and immunology-what do we know so far? Coronavirus disease 2019 (COVID-19): what we need to know Caution in the time of rashes and COVID-19 diagnosis and management of the drug hypersensitivity reactions in Coronavirus disease 19: an EAACI Position Paper The adverse skin reactions of health care workers using personal protective equipment for COVID-19 Frequent hand washing for COVID-19 prevention can cause hand dermatitis: management tips Drugs targeting various stages of the SARS-CoV-2 life cycle: exploring promising drugs for the treatment of Covid-19 Histological pattern in COVID-19-induced viral rash Polymorphic cutaneous manifestations of COVID-19 infection in a single viral host Association of acute urticaria with Mycoplasma pneumoniae infection in hospitalized children Urticaria and COVID-19: a review Cutaneous manifestations of the Coronavirus Disease 2019 (COVID-19): a brief review Management of urticaria in COVID-19 patients: a systematic review Cutaneous manifestations of COVID-19: an evidence-based review Management of urticaria in COVID-19 patients: a systematic Clinicopathologic aspects of a papulovesicular eruption in a patient with COVID-19 The broad spectrum of dermatological manifestations in COVID-19: clinical and histopathological features learned from a series of 34 cases Herpes zoster (shingles) complicating the course of COVID19 infection Reply to "Varicella-like exanthem as a specific COVID-19-associated skin manifestation: Multicenter case series of 22 patients": to consider varicella-like exanthem associated with COVID-19, virus varicella zoster and virus herpes simplex must be ruled out Varicella-like exanthem as a specific COVID-19-associated skin manifestation: multicenter case series of 22 patients Comment on 'Clinical and histological characterization of vesicular COVID-19 rashes: a prospective study in a tertiary care hospital'. Pseudoherpetic Grover disease seems to occur in patients with COVID-19 infection Clinical and histological characterization of vesicular COVID-19 rashes: a prospective study in a tertiary care hospital Pernio-like skin lesions associated with COVID-19: a case series of 318 patients from 8 countries Chilblain-like lesions in children following suspected COVID-19 infection Chilblain-like lesions in pediatrics dermatological outpatients during the COVID-19 outbreak Diagnostic and prognostic values of cutaneous manifestations in COVID-19 Cutaneous manifestations of COVID-19 in children (and adults): a virus that does not discriminate Symmetric cutaneous vasculitis in COVID-19 pneumonia Small vessel vasculitis caused by hepatitis B virus immune complexes: small vessel vasculitis and HBsAG Kawasaki-like disease: emerging complication during the COVID-19 pandemic COVID-19 can present with a rash and be mistaken for dengue Urticarial vasculitis in a COVID-19 recovered patient COVID-19 and cutaneous vasculopathy: what is known? Erythema multiforme-like eruption in patients with COVID-19 infection: clinical and histological findings Pityriasis rosea as a cutaneous manifestation of COVID-19 infection Grover-like skin eruption: another cutaneous manifestation in a COVID-19 patient Skin manifestations in COVID-19: prevalence and relationship with disease severity Eruption as a clinical manifestation of COVID-19: photographs of a patient Cutaneous signs in COVID-19 patients: a review A distinctive skin rash associated with coronavirus disease 2019? COVID toes"): histologic, immunofluorescence, and immunohistochemical study of 17 cases Skin hyperpigmentation in COVID-19 patients: is polymyxin B the culprit? Severe acute dried gangrene in COVID-19 infection: a case report Nail care for healthcare workers during COVID-19 pandemic Large sacral/buttocks ulcerations in the setting of coagulopathy: a case series establishing the skin as a target organ of significant damage and potential morbidity in patients with severe COVID-19 Novel coronavirus in a 15-day-old neonate with clinical signs of sepsis, a case report Lichenoid eruptions with interface dermatitis and necrotic subepidermal blister associated with COVID-19 Drug reaction with eosinophilia and systemic symptoms syndrome in a patient with COVID-19 Late-onset AGEP-like skin pustular eruption following COVID-19: a possible association characteristics, laboratory findings and outcomes in acro-ischemia in COVID-19 patients. Vasc Health Risk Manag Dermatologists' role in the diagnosis and management of coronavirus disease 2019 coagulopathy COVID-19-related IgA vasculitis Leucocytoclastic vasculitis in a patient with COVID-19 with positive SARS-CoV-2 PCR in skin biopsy Paniculitis eosinofílica secundaria a infección por COVID-19 Periorbital erythema as a presenting sign of COVID-19 COVID-19 related anagen effluvium Androgenetic alopecia present in the majority of patients hospitalized with COVID-19: the "Gabrin sign The red half-moon nail sign: a novel manifestation of coronavirus infection Nailfold capillaroscopy findings in patients with coronavirus disease 2019: broadening the spectrum of COVID-19 microvascular involvement Cutaneous manifestations in COVID-19: a skin rash in a child Cutaneous manifestations related to coronavirus disease 2019 (COVID-19): a prospective study from China and Italy COVID-19 and cutaneous manifestations: a systematic review Geriatric skin care in the era of COVID-19 Spectrum of COVID-19 in children Skin manifestations of COVID-19 in children: part 3 Erythema multiforme and Kawasaki disease associated with COVID-19 infection in children Covid-19 pandemic and the skin Kawasaki-like disease in children with COVID-19 COVID-19-related skin manifestations: update on therapy Cutaneous manifestations in patients with COVID-19: a preliminary review of an emerging issue Maculopapular skin eruptions associated with Covid-19: a systematic review The spectrum of COVID-19-associated dermatologic manifestations: An international registry of 716 patients from 31 countries Cutaneous sıde-effects of the potential COVID-19 drugs Characterizing the adverse dermatologic effects of hydroxychloroquine: a systematic review Hydroxychloroquine-induced hyperpigmentation in systemic diseases: prevalence, clinical features and risk factors: a cross-sectional study of 41 cases Drug-induced hair colour changes Hydroxychloroquineinduced inverse psoriasis Hydroxychloroquine-induced Stevens-Johnson syndrome in COVID-19: a rare case report Acute generalized exanthematous pustulosis induced by hydroxychloroquine prescribed for COVID-19 Hydroxychloroquine in dermatology and beyond: recent update Cutaneous reactions in patients with chronic hepatitis C treated with peginterferon and ribavirin Acute generalized exanthematous pustulosis induced by HIV postexposure prophylaxis with lopinavir-ritonavir Eczema-like lesions and disruption of therapy in patients treated with interferon-alfa and ribavirin for chronic hepatitis C: the value of an interdisciplinary assessment Acute generalized exanthematous pustulosis due to tocilizumab in a rheumatoid arthritis patient Fatal DRESS syndrome under tocilizumab treatment for seronegative polyarthritis Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial Compassionate use of remdesivir for patients with severe Covid-19 Simonds AK, Practical Handbook Noninvasive Ventilation Sheffield Enanthem in patients with COVID-19 and skin rash Oral manifestations of COVID-19 disease: a review article Clinical and histopathological features and potential pathological mechanisms of skin lesions in COVID-19: review of the literature Immunohistopathological findings of severe cutaneous adverse drug reactions Histopathological study of a broad spectrum of skin dermatoses in patients affected or highly suspected of infection by COVID-19 in the northern part of Italy: analysis of the many faces of the viral-induced skin diseases in previous and new reported cases Clinical and histopathological findings of cutaneous manifestations of COVID-19 patients Cutaneous, skin histopathological manifestations and relationship to COVID-19 infection patients A clinical, histopathological and laboratory study of 19 consecutive Italian paediatric patients with chilblain-like lesions: lights and shadows on the relationship with COVID-19 infection Clustered cases of acral perniosis: clinical features, histopathology, and relationship to COVID-19 A generalized purpuric eruption with histopathologic features of leucocytoclastic vasculitis in a patient severely ill with COVID-19 Cutaneous manifestations of COVID-19: a preliminary review COVID-19 pandemic and the skin: what should dermatologists know? Mass quarantine measures in the time of COVID-19 pandemic: psychosocial implications for chronic skin conditions and a call for qualitative studies Geriatric challenges in the new coronavirus disease-19 (COVID-19) pandemic: a systematic review Impact of the COVID-19 pandemic on the course and management of chronic inflammatory immune-mediated skin diseases: what's the evidence? Position statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes on quality of life issues in dermatologic patients during the COVID-19 pandemic Patients with specific skin disorders who are affected by COVID-19: what do experiences say about management strategies? A systematic review Geriatric dermatoses: a clinical review of skin diseases in an aging population COVID-19 related stress exacerbates common physical and mental pathologies and affects treatment Dermatology staff participate in fight against Covid-19 in China Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics A challenging case of psoriasis flare-up after COVID-19 infection COVID-19 and psoriasis: biologic treatment and challenges Cutaneous manifestations and considerations in COVID-19 pandemic: a systematic review Association of COVID-19 with skin diseases and relevant biologics: a cross-sectional study using nationwide claim data in South Korea Herpes zoster cases increased during COVID-19 outbreak. Is it possible a relation? The role of androgens in COVID-19 Plastic surgery and the COVID-19 pandemic: a review of clinical guidelines Skin cancer triage and management during COVID-19 pandemic Relationship of treatment delay with surgical defect size from keratinocyte carcinoma (basal cell carcinoma and squamous cell carcinoma of the skin) Dermatologic reactions to disinfectant use during the COVID-19 pandemic Skin changes attributed to protective measures against COVID-19: a compilation Frequent handwashing amidst the COVID-19 outbreak: prevention of hand irritant contact dermatitis and other considerations The role of occupational dermatology in the COVID-19 outbreak Overzealous hand hygiene during the COVID 19 pandemic causing an increased incidence of hand eczema among general population Update to device-related pressure ulcers: SE-CURE prevention. COVID-19, face masks and skin damage treatment of nasal bridge ulceration related to protective measures for the COVID-19 epidemic Occupational skin disease among health care workers during the coronavirus (COVID-19) epidemic Prevention and occupational hazards for the skin during COVID-19 pandemic The prevalence, characteristics, and prevention status of skin injury caused by personal protective equipment among medical staff in fighting COVID-19: a multicenter, cross-sectional study Aquagenic acrokeratoderma due to frequent handwashing during the COVID-19 pandemic outbreak Surgical mask dermatitis caused by formaldehyde (releasers) during the COVID-19 pandemic Retroauricular dermatitis with vehement use of ear loop face masks during COVID-19 pandemic Protecting medical staff from skin injury/disease caused by personal protective equipment during epidemic period of COVID-19: experience from China COVID-19 and personal protective equipment: treatment and prevention of skin conditions related to the occupational use of personal protective equipment The effects of the face mask on the skin underneath: a prospective survey during the COVID-19 pandemic novel coronavirus disease epidemic: skin protection for healthcare workers must not be ignored Skin reactions to non-glove personal protective equipment: an emerging issue in the COVID-19 pandemic Role of dermatologists in the uprising of the novel corona virus (COVID-19): perspectives and opportunities COVID-19 with dermatologic manifestations and implications: an unfolding conundrum The authors thank the Department of Infectious diseases of Kermanshah and Babol Universities of Medical Sciences. The authors declare that there are no conflict of interests.MOHSENI AFSHAR ET AL.